Sarepta Therapeutics Inc [SRPT] stock prices are down -0.76% to $18.2 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SRPT shares have lost -9.99% over the last week, with a monthly amount glided 10.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on July 29, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $37 for it. Previously, JP Morgan upgraded its rating to Neutral on July 29, 2025, and kept the price target unchanged to $24. On July 29, 2025, upgrade upgraded it’s rating to Equal Weight but maintained its price target of $22 on the stock. H.C. Wainwright reiterated its Sell rating but stick to its price target of $5 on July 29, 2025. Bernstein initiated its recommendation with a Mkt Perform and recommended $13 as its price target on July 29, 2025. Barclays downgraded its rating to Underweight for this stock on July 28, 2025, but kept the price target unchanged to $10. In a note dated July 25, 2025, JP Morgan downgraded an Underweight rating on this stock.
The stock price of Sarepta Therapeutics Inc [SRPT] has been fluctuating between $10.41 and $140.10 over the past year. Currently, Wall Street analysts expect the stock to reach $38.63 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $18.2 at the most recent close of the market. An investor can expect a potential return of 112.25% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
The Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 2.48B for trailing twelve months, representing a surge of 68.38%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.04 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.78 points at the first support level, and at 17.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.64, and for the 2nd resistance point, it is at 19.07.
Ratios To Look Out For
It’s worth pointing out that Sarepta Therapeutics Inc [NASDAQ:SRPT]’s Current Ratio is 2.89. Also, the Quick Ratio is 1.81, while the Cash Ratio stands at 0.56. Considering the valuation of this stock, the price to sales ratio is 0.72, the price to book ratio is 1.31.
Transactions by insiders
Recent insider trading involved Sarepta Therapeutics, Inc., Shareholder, that happened on Aug 13 ’25 when 9.27 million shares were purchased. Director, Nicaise Claude completed a deal on Mar 12 ’25 to sell 2491.0 shares. Meanwhile, Director Nicaise Claude bought 2491.0 shares on Mar 12 ’25.
